Lorena Usero

Lorena Usero

Auto-generated profile, based on publicly available information

Lorena Usero


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
LULorena Usero
Lorena Usero
GYGuillermo Yoldi
Guillermo Yoldi
CFClaudia Faundez-Vidiella
Claudia Faundez-Vidiella
NDNora Diéguez-Martínez
Nora Diéguez-Martínez
SBSandra Barbosa
Sandra Barbosa
Jose M LizcanoJose M Lizcano
Jose M Lizcano
Acquired chemoresistance is common in advanced pancreatic cancer (PCa), highlighting the need to improve the efficacy of current chemotherapy regimens. In this study, we investigated the first-in-class molecule ABTL0812 (Ibrilatazar), a potent inducer of endoplasmic reticulum (ER) stress currently in clinical trial for advanced PCa, as a strategy to improve the effectiveness of standard chemotherapy.ABTL0812 enhanced the efficacy of standard chemotherapies FOLFIRINOX and gemcitabine/nab-paclitaxel in a panel of pancreatic ductal adenocarcinoma cell lines and tumor xenografts, and combined treatments showed increased levels of ER stress. ABTL0812, alone or in combination with FOLFIRINOX exerted immunomodulatory effects in the KRAS/TP53 (KPC) genetically engineered mice, by impairing the intratumoral infiltration of T regulatory (Treg) cells, the major immunosuppressive cell subset in the PCa tumors. In engrafted syngeneic PCa tumors, ABTL0812 treatment, alone or in combination with FOLFIRINOX, impaired the infiltration of Treg cells, myeloid-derived suppressor cells and exhausted CD4+/CD8+ T cells. Mechanistically, we show that ABTL0812 inhibits the differentiation of CD4+ naïve T cells into Treg cells induced by TGFb. ABTL0812 also impairs the protumoral activity of stromal cells of PCa, by inhibiting the secretion of TGFb from pancreatic stellate cells levels and of the Treg cell chemoattractant CXCL12 from patient-derived pancreatic CAFs. This work establishes that ER stress inducers such as ABTL0812 potentiate the anticancer activity of the standard chemotherapy regimens currently used in PCa, and suggests their potential to improve the effectiveness of immunotherapy.